Clinical-Trials

Clinical-Trials funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.

NIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

This NIH PAR-26-116 cooperative agreement supports translational research led by extramural investigators that uses NIH Clinical Center infrastructure through a planned collaboration with NIH intramural investigators.

Status: Open Type: Grant Amount: Up to US$500,000 direct costs per year Deadline: Mar 5, 2027 Location: United States

NIH PA-24-193: Pathway to Independence (K99/R00, Independent Clinical Trial Required)

A parent NIH career-development mechanism for mentored postdoctoral candidates transitioning to independent investigator status while proposing an independent clinical trial, with recurring annual review cycles into 2027.

Status: Open Type: Grant Amount: R00 phase: up to $249,000 total cost per year Deadline: Jun 12, 2026 Location: United States

NIH RFA-NS-26-001: Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

This NIH opportunity funds research that uses expanded-access data from investigational ALS treatments to support studies in patient populations that cannot enter ongoing clinical trials, with $40,000,000 in FY 2026/27 program funding and a four-award cap for the cycle.

Status: Open Type: Cooperative Agreement Amount: $40,000,000 Deadline: Nov 10, 2026 Location: United States

PAR-27-013: Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (U24)

The NHLBI PAR-27-013 funding opportunity supports Data Coordinating Center (DCC) teams that coordinate multi-site investigator-initiated clinical trials in a milestone-driven cooperative agreement, submitted alongside a companion Clinical Coordinating Center application.

Status: Open Type: Grant Deadline: Jun 2, 2026 Location: United States and Collaborative trial networks

RFA-CA-27-006: NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)

A federal clinical-research cooperative agreement for US institutions to serve as NCORP research hubs that run cancer prevention, treatment, symptom-management, and care-delivery trials in community settings.

Status: Open Type: Grant Amount: $74,500,000 total program funding in the FY2027 notice, with up to 7 awards Deadline: Sep 18, 2026 Location: United States

RFA-CA-27-016: The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)

NIH/NCI’s ETCTN NOFO seeks institutions that can lead early-phase cancer therapeutic trials within the NCI Cancer Therapy Evaluation Program, using the UM1 cooperative agreement model with a strong focus on trial activation, accrual, and mentorship for early career investigators.

Status: Open Type: Grant Amount: NIH intends to commit $11.8 million in FY 2027 to fund four to six awards Deadline: Jun 30, 2026 Location: United States and Canada

RFA-MH-27-135: Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (R01 Clinical Trials Required)

NIH/NIMH is seeking R01 research grants focused on rigorous clinical trials and trial methods for rapid-acting psychotropic interventional drug development, with a FY2027 budget totaling about $5.5M.

Status: Open Type: Grant Amount: NIH/NIMH total FY2027 funding $5,000,000 for up to 5 awards + NIDA $500,000 for up to 1 award Deadline: Oct 10, 2026 Location: United States

RFA-NS-25-021: BRAIN Initiative Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3)

NIH BRAIN Initiative cooperative agreement to accelerate translational development of recording and modulation devices for CNS disorders through milestone-driven UG3/UH3 funding and small clinical studies requiring FDA IDE pathways.

Status: Open Type: Grant Amount: NIH anticipates $10M per year; estimated 5 to 7 awards. UG3: up to $500,000 direct costs/year Deadline: Sep 28, 2026 Location: United States

RFA-OD-27-005: INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)

A trans-NIH R61/R33 phased mechanism for developing and advancing translational clinical trials for co-occurring conditions in people with Down syndrome, with a maximum five-year project period and an upcoming 2026/2027 filing rhythm.

Status: Open Type: Grant Deadline: Oct 15, 2026 Location: United States